You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 13, 2024

~ Buy the OLINVYK (oliceridine) Drug Profile, 2024 PDF Report in the Report Store ~

OLINVYK Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Olinvyk patents expire, and what generic alternatives are available?

Olinvyk is a drug marketed by Trevena and is included in one NDA. There are five patents protecting this drug.

This drug has fifty-one patent family members in twenty-three countries.

The generic ingredient in OLINVYK is oliceridine. One supplier is listed for this compound. Additional details are available on the oliceridine profile page.

DrugPatentWatch® Generic Entry Outlook for Olinvyk

Olinvyk was eligible for patent challenges on October 30, 2024.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 23, 2032. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for OLINVYK?
  • What are the global sales for OLINVYK?
  • What is Average Wholesale Price for OLINVYK?
Summary for OLINVYK
International Patents:51
US Patents:5
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 32
Patent Applications: 48
Drug Prices: Drug price information for OLINVYK
What excipients (inactive ingredients) are in OLINVYK?OLINVYK excipients list
DailyMed Link:OLINVYK at DailyMed
Drug patent expirations by year for OLINVYK
Drug Prices for OLINVYK

See drug prices for OLINVYK

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for OLINVYK
Generic Entry Date for OLINVYK*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for OLINVYK

OLINVYK is protected by five US patents and one FDA Regulatory Exclusivity.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of OLINVYK is ⤷  Sign Up.

This potential generic entry date is based on patent ⤷  Sign Up.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting OLINVYK

Opioid receptor ligands and methods of using and making same
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: MANAGEMENT OF ACUTE PAIN BY INTRAVENOUS INJECTION


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: MANAGEMENT OF ACUTE PAIN BY INTRAVENOUS INJECTION

Opioid receptor ligands and methods of using and making same
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: MANAGEMENT OF ACUTE PAIN BY INTRAVENOUS INJECTION

Opioid receptor ligands and methods of using and making same
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: MANAGEMENT OF ACUTE PAIN BY INTRAVENOUS INJECTION

Opioid receptor ligands and methods of using and making same
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: MANAGEMENT OF ACUTE PAIN BY INTRAVENOUS INJECTION

FDA Regulatory Exclusivity protecting OLINVYK

NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Trevena OLINVYK oliceridine SOLUTION;INTRAVENOUS 210730-001 Oct 30, 2020 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Trevena OLINVYK oliceridine SOLUTION;INTRAVENOUS 210730-003 Oct 30, 2020 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Trevena OLINVYK oliceridine SOLUTION;INTRAVENOUS 210730-002 Oct 30, 2020 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Trevena OLINVYK oliceridine SOLUTION;INTRAVENOUS 210730-001 Oct 30, 2020 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
Trevena OLINVYK oliceridine SOLUTION;INTRAVENOUS 210730-002 Oct 30, 2020 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for OLINVYK

When does loss-of-exclusivity occur for OLINVYK?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 12230761
Patent: Opioid receptor ligands and methods of using and making same
Estimated Expiration: ⤷  Sign Up

Patent: 17200745
Patent: Opioid receptor ligands and methods of using and making same
Estimated Expiration: ⤷  Sign Up

Brazil

Patent: 2013024136
Patent: ligandos de receptor de opióide e métodos de usar e fabricar os mesmos
Estimated Expiration: ⤷  Sign Up

Canada

Patent: 30742
Patent: OXANES SUBSTITUES COMME LIGANDS DE RECEPTEUR OPIOIDE ET METHODES D'UTILISATION ET DE FABRICATION ASSOCIEES (SUBSTITUTED OXANES AS OPIOID RECEPTOR LIGANDS AND METHODS OF USING AND MAKING SAME)
Estimated Expiration: ⤷  Sign Up

China

Patent: 3702561
Patent: Opioid receptor ligands and methods of using and making same
Estimated Expiration: ⤷  Sign Up

Croatia

Patent: 0171021
Estimated Expiration: ⤷  Sign Up

Cyprus

Patent: 19057
Estimated Expiration: ⤷  Sign Up

Denmark

Patent: 88403
Estimated Expiration: ⤷  Sign Up

Patent: 90415
Estimated Expiration: ⤷  Sign Up

Eurasian Patent Organization

Patent: 5456
Patent: ЛИГАНДЫ ОПИОИДНЫХ РЕЦЕПТОРОВ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ И ПОЛУЧЕНИЯ (OPIOID RECEPTOR LIGANDS AND METHODS OF USING AND MAKING SAME)
Estimated Expiration: ⤷  Sign Up

Patent: 1391332
Patent: ЛИГАНДЫ ОПИОИДНЫХ РЕЦЕПТОРОВ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ И ПОЛУЧЕНИЯ
Estimated Expiration: ⤷  Sign Up

European Patent Office

Patent: 88403
Patent: LIGANDS DE RÉCEPTEURS OPÏOIDES, ET LEURS PROCÉDÉS D'UTILISATION ET DE PRODUCTION (OPIOID RECEPTOR LIGANDS AND METHODS OF USING AND MAKING SAME)
Estimated Expiration: ⤷  Sign Up

Patent: 90415
Patent: LIGANDS DE RÉCEPTEURS OPÏOIDES, ET LEURS PROCÉDÉS D'UTILISATION ET DE PRODUCTION (OPIOID RECEPTOR LIGANDS AND METHODS OF USING AND MAKING SAME)
Estimated Expiration: ⤷  Sign Up

Patent: 72076
Patent: LIGANDS DE RÉCEPTEURS OPÏOIDES, ET LEURS PROCÉDÉS D'UTILISATION ET DE PRODUCTION (OPIOID RECEPTOR LIGANDS AND METHODS OF USING AND MAKING SAME)
Estimated Expiration: ⤷  Sign Up

Hong Kong

Patent: 50984
Patent: 阿片樣物質受體配體以及使用和製備其的方法 (OPIOID RECEPTOR LIGANDS AND METHODS OF USING AND MAKING SAME)
Estimated Expiration: ⤷  Sign Up

Hungary

Patent: 32948
Estimated Expiration: ⤷  Sign Up

Patent: 54055
Estimated Expiration: ⤷  Sign Up

Israel

Patent: 8506
Patent: ליגנדים של קולטן אופיואיד ותכשירי רוקחות המכילים אותם (Opioid receptor ligands and pharmaceutical compositions comprising them)
Estimated Expiration: ⤷  Sign Up

Patent: 3318
Patent: ליגנדים של קולטן אופיואיד ושיטות לשימוש בהם ולהכנתם (Opioid receptor ligands and methods of using and making same)
Estimated Expiration: ⤷  Sign Up

Patent: 2165
Patent: ליגנדים של קולטן אופיואיד ושיטות לשימוש בהם ולהכנתם (Opioid receptor ligands and methods of using and making same)
Estimated Expiration: ⤷  Sign Up

Patent: 4407
Patent: ליגנדים של קולטן אופיואיד ושיטות לשימוש בהם ולהכנתם (Opioid receptor ligands and methods of using and making same)
Estimated Expiration: ⤷  Sign Up

Japan

Patent: 12169
Estimated Expiration: ⤷  Sign Up

Patent: 43949
Estimated Expiration: ⤷  Sign Up

Patent: 49341
Estimated Expiration: ⤷  Sign Up

Patent: 23683
Estimated Expiration: ⤷  Sign Up

Patent: 48750
Estimated Expiration: ⤷  Sign Up

Patent: 14508811
Estimated Expiration: ⤷  Sign Up

Patent: 16155843
Patent: オピオイド受容体リガンド並びにそれらの使用方法及び製造方法 (OPIOID RECEPTOR LIGANDS AND METHODS OF USING AND MAKING THE SAME)
Estimated Expiration: ⤷  Sign Up

Patent: 18048193
Patent: オピオイド受容体リガンド並びにそれらの使用方法及び製造方法 (OPIOID RECEPTOR LIGANDS AND METHODS OF USING AND MAKING THE SAME)
Estimated Expiration: ⤷  Sign Up

Patent: 20073570
Patent: オピオイド受容体リガンド並びにそれらの使用方法及び製造方法 (OPIOID RECEPTOR LIGANDS AND METHODS OF USING AND MAKING THE SAME)
Estimated Expiration: ⤷  Sign Up

Patent: 21176885
Patent: オピオイド受容体リガンド並びにそれらの使用方法及び製造方法 (OPIOID RECEPTOR LIGAND AND METHODS OF USING AND MAKING THE SAME)
Estimated Expiration: ⤷  Sign Up

Patent: 23075282
Patent: オピオイド受容体リガンド並びにそれらの使用方法及び製造方法
Estimated Expiration: ⤷  Sign Up

Lithuania

Patent: 88403
Estimated Expiration: ⤷  Sign Up

Montenegro

Patent: 754
Patent: LIGANDI OPIOIDNIH RECEPTORA I POSTUPCI NJIHOVE UPOTREBE I PRIPREME (OPIOID RECEPTOR LIGANDS AND METHODS OF USING AND MAKING SAME)
Estimated Expiration: ⤷  Sign Up

New Zealand

Patent: 5993
Patent: Opioid receptor ligands and methods of using and making same
Estimated Expiration: ⤷  Sign Up

Patent: 3143
Patent: Opioid receptor ligands and methods of using and making same
Estimated Expiration: ⤷  Sign Up

Poland

Patent: 88403
Estimated Expiration: ⤷  Sign Up

Patent: 90415
Estimated Expiration: ⤷  Sign Up

Portugal

Patent: 88403
Estimated Expiration: ⤷  Sign Up

Patent: 90415
Estimated Expiration: ⤷  Sign Up

Serbia

Patent: 111
Patent: LIGANDI OPIOIDNIH RECEPTORA I POSTUPCI NJIHOVE UPOTREBE I PRIPREME (OPIOID RECEPTOR LIGANDS AND METHODS OF USING AND MAKING SAME)
Estimated Expiration: ⤷  Sign Up

Slovenia

Patent: 88403
Estimated Expiration: ⤷  Sign Up

South Korea

Patent: 1991326
Estimated Expiration: ⤷  Sign Up

Patent: 1991327
Estimated Expiration: ⤷  Sign Up

Patent: 2129247
Estimated Expiration: ⤷  Sign Up

Patent: 140047599
Patent: OPIOID RECEPTOR LIGANDS AND METHODS OF USING AND MAKING SAME
Estimated Expiration: ⤷  Sign Up

Patent: 180100453
Patent: 오피오이드 수용체 리간드와 그 용도 및 제조방법 (Opioid Receptor Ligands and Methods of Using and Making Same)
Estimated Expiration: ⤷  Sign Up

Patent: 190072665
Patent: 오피오이드 수용체 리간드와 그 용도 및 제조방법 (Opioid Receptor Ligands and Methods of Using and Making Same)
Estimated Expiration: ⤷  Sign Up

Spain

Patent: 32009
Estimated Expiration: ⤷  Sign Up

Patent: 57549
Estimated Expiration: ⤷  Sign Up

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering OLINVYK around the world.

Country Patent Number Title Estimated Expiration
Denmark 3290415 ⤷  Sign Up
European Patent Office 3290415 LIGANDS DE RÉCEPTEURS OPÏOIDES, ET LEURS PROCÉDÉS D'UTILISATION ET DE PRODUCTION (OPIOID RECEPTOR LIGANDS AND METHODS OF USING AND MAKING SAME) ⤷  Sign Up
Japan 2016155843 オピオイド受容体リガンド並びにそれらの使用方法及び製造方法 (OPIOID RECEPTOR LIGANDS AND METHODS OF USING AND MAKING THE SAME) ⤷  Sign Up
Montenegro 02754 LIGANDI OPIOIDNIH RECEPTORA I POSTUPCI NJIHOVE UPOTREBE I PRIPREME (OPIOID RECEPTOR LIGANDS AND METHODS OF USING AND MAKING SAME) ⤷  Sign Up
Eurasian Patent Organization 025456 ЛИГАНДЫ ОПИОИДНЫХ РЕЦЕПТОРОВ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ И ПОЛУЧЕНИЯ (OPIOID RECEPTOR LIGANDS AND METHODS OF USING AND MAKING SAME) ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.